Which Merck p53-binding compounds are covered by patents?
Merck has worked on multiple p53-related programs over the years, including small molecules intended to restore or modulate p53 function, but the specific answer to “Merck p53 binding compound patent” depends on the exact compound name/series (or the assignee details on the patent family).
If you share any of the following, I can point to the most relevant patent(s) and their status more precisely:
- the compound code name/structure (e.g., a lead identifier from Merck’s publications or a product reference)
- a target license number, collaborator name, or inventors
- any patent number, WO/EP/US publication number, or a link
How to search for the right Merck patent if you only know it binds p53
A practical way to identify the correct patent family is to search by combinations of:
- Assignee: “Merck” (or “Merck KGaA” and “Merck Sharp & Dohme” depending on jurisdiction)
- Keywords: “p53”, “p53 binding”, “MDM2” (if the mechanism is MDM2–p53 axis), “reactivator”, “stabilizer”, “small molecule”
- Patent text fields: title/abstract claims and the “Summary of invention” sections
You can also narrow by known p53-compound mechanism:
- MDM2 inhibitors (meant to prevent MDM2 from degrading p53)
- direct p53 reactivators (meant to restore mutant p53 conformation and function)
- other modulators that lead to increased p53 activity
When do p53-binding compound patents typically expire?
Patent term is typically 20 years from the earliest effective filing date, with possible adjustments/exclusivity depending on jurisdiction and whether any supplementary protection mechanisms apply. The exact expiry date for a Merck p53-binding compound cannot be determined without the specific patent family (or at least the earliest priority year).
Are there freedom-to-operate or generic/biosimilar-style implications?
For small-molecule p53-binding drugs, the key issues are usually:
- whether a specific claim is still in force in the country of interest
- whether the marketed product falls within the scope of the remaining claims
- whether there are carve-outs (e.g., method-of-use claims vs composition claims)
This again requires the exact compound/patent numbers you want evaluated.
What I need from you to give the exact Merck patent answer
To identify the Merck “p53 binding compound patent” precisely, please provide one:
- the compound name/code, or
- a patent publication number (WO/US/EP) you saw, or
- a link to the Merck molecule (press release, paper, clinicaltrials page, or listing)
Once you provide that, I can tell you which Merck patent family covers it, what claims relate to p53 binding/reactivation, and what the likely remaining term looks like based on filing/priority data.